Skip to content
Homepage
Author:
SEED Therapeutics
Posted Date:
June 2, 2026
SEED Therapeutics Highlights Clinical Advancement and Broad Oncology Potential of ST-01156, an RBM39 Molecular Glue Degrader in First-in-Human in Phase 1 Studies, at ASCO 2026
SEED Therapeutics
June 2, 2026
SEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting
SEED Therapeutics
May 28, 2026
SEED Therapeutics Reports Tumor Eradication in a Neuroblastoma In Vivo Model with Clinical-Stage RBM39 Molecular Glue Degrader ST-01156
SEED Therapeutics
May 24, 2026
SEED Therapeutics Announces Poster Presentation at AACR Annual Meeting 2026
SEED Therapeutics
May 21, 2026
